Vaccine Efficacy of MVA-BN Against Mpox Infection
Wednesday, 18 September 2024, 01:29
Understanding Vaccine Efficacy Against Mpox
The MVA-BN vaccine, a modified vaccinia Ankara-Bavarian Nordic formulation, has demonstrated moderate effectiveness in preventing mpox infection based on an emulated target trial. This single-dose vaccine illustrates the ongoing efforts in managing outbreaks and improving prophylaxis options for those at risk, such as individuals living with HIV.
Significance of Vaccination Strategies
- Vaccine strategies are vital in public health, especially in raising immunization rates among vulnerable populations.
- The role of social determinants of health (SDOH) remains paramount in addressing disparities in healthcare access and outcomes.
- Healthcare professionals emphasize the importance of vaccines in preventative measures against outbreaks and chronic infection diseases.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.